Moreover, the triplet combination of another small molecule FAK inhibitor, defactinib, PLD, and anti-mouse PD-L1 showed optimal tumor growth inhibition in the CT26 model compared to the other treated groups. This evidence concerns the gene GPLD1 and neoplasm.